Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• 36th Congress Czech Nutrition Society 2020 Hradec Kralove CZ  + (36th annual international congress of Czech Nutrition Society, Hradec Kralove, Czech Republic, 2020)
• 37th Annual Meeting of the ISHR-ES 2023 Porto PT  + (37th Annual Meeting of the ISHR-ES, Porto, Portugal, 2023)
• MiPschool Baton Rouge LA US 2009  + (3^rd MiP''summer school'' on Mitochondrial Respiratory Physiology, 2009 June 17-23, Baton Rouge, Louisiana US.)
• Eugeny I. Schwartz Conference 2015  + (3^rd Russian Congress with International Participation “Molecular Basis of Clinical Medicine: State-of-the-Art and Perspectives” dedicated to the memory of Eugeny I. Schwartz, St. Petersburg , Russia;)
• Ophthalmology Conference 2018 Rome IT  + (3rd Edition of International Conference on Eye and Vision, Rome, Italy; 2018)
• METABO & Cancer 2019 Marseille FR  + (3rd edition - Metabolism and Cancer Meeting, Marseille, France, 2019)
• MacDonald 2014 Abstract MiP2014  + (4-hydroxy-2-oxoglutarate aldolase (HOGA) i … 4-hydroxy-2-oxoglutarate aldolase (HOGA) is a bi-functional mitochondrial enzyme, expressed predominantly in liver and kidney. HOGA is involved in the hydroxyproline degradation pathway (HOGglyoxylate+pyruvate), and mutations in HOGA result in primary Hyperoxaluria Type III, characterized by excessive oxalate production and kidney stone deposition [1]. We hypothesized that HOGA may also be involved in the TCA cycle as an oxaloacetate decarboxylase (oxaloacetatepyruvate; Fig. 1), which may allow the TCA cycle to turnover in the absence of pyruvate and/or excess oxaloacetate. </br>The kinetics of HOGA with substrates HOG and oxaloacetate were investigated by measuring the ''K''’_m and ''k''_cat of recombinant human HOGA, using an LDH-coupled microplate assay. The role of HOGA in the TCA cycle was investigated using mitochondria, isolated from rat liver and kidney, where HOGA is highly expressed, and brain and heart, where expression is lower. ADP-stimulated malate respiration was measured relative to ADP-malate + pyruvate (M:PM), using oxygraphy (Oroboros Oxygraph-2k, note malate was used as oxaloacetate cannot cross the inner mitochondrial membrane).</br> </br>While HOGA was 75% less efficient at cleaving oxaloacetate than its other substrate, HOG (''K''’_m/''k''_cat), the ''K''’_m for oxaloacetate was within range of that estimated for TCA intermediates (''K''’_m,ox=129±8 µM, ''k''_cat,ox=0.52±0.01 s^-1; ''K''’_m,HOG=55±5 µM, ''k''_cat,HOG=1.01±0.03 s^-1). Overall, HOGA appears to use the same catalytic mechanism to cleave both HOG and oxaloacetate substrates. Interestingly, the TCA cycle intermediate a-ketoglutarate was found to be a competitive inhibitor of HOGA oxaloacetate decarboxylase activity (''K''_i=2.8 mM). Mitochondria from rat liver had the highest M:PM respiration relative to all other organs (0.46±0.05, ''P''<0.05). Though kidney had a higher M:PM respiration than heart (0.27±0.02 vs 0.15±0.02, ''P''<0.05 in kidney and heart, respectively), brain respired as well as kidney (0.33±0.04).</br></br> </br>In summary, HOGA cleaves oxaloacetate and HOG using the same catalytic mechanism but was less efficient with oxaloacetate. Liver and kidney have high HOGA expression, and mitochondria from both respire significantly better on malate relative to PM than heart mitochondria. The brain respires just as well with malate compared to kidney, and this may be due to high expression of malic enzyme, which can convert malate directly to pyruvate (Fig. 1). Malate supported respiration in HOGA overexpressing cells will confirm the direct role of HOGA in the TCA cycle.ession of malic enzyme, which can convert malate directly to pyruvate (Fig. 1). Malate supported respiration in HOGA overexpressing cells will confirm the direct role of HOGA in the TCA cycle.)
• MBSJ 2018 Yokohama JP  + (41st Annual Meeting of the Molecular Biology Society of Japan, Yokohama, Japan, 2018.)
• The 42nd Annual Meeting of The Molecular Biology Society of Japan  + (42nd Annual Meeting of The Molecular Biology Society of Japan, Kurume, 2018)
• ISOTT 2015  + (43^rd Annual Meeting of the International Society on Oxygen Transport to Tissue (ISOTT))

• AICBC 2024 Navi Mumbai IN  + (46^th All India Cell Biology Conference, Navi Mumbai, India, 2024)
• 46th ISOBM Congress 2019 Athens GR  + (46th annual congres of the International Society of Oncology and Biomarkers, Athens, Greece, 2019)
• ESCI 2015  + (49th Annual Scientific Meeting of the European Society for Clinical Investigation, Cluj-Napoca, Romania; [http://www.esci.eu.com/meetings/ ESCI 2015])
• SMRM2014 Manipal IN  + (4^th Annual Conference of the Society for Mitochondrial Research and Medicine, Kolkata, India.)
• MiPschool Druskininkai LT 2010  + (4^th MiP''summer school'' on Mitochondrial Respiratory Physiology, 2010 June 10-16, Druskininkai, Lithuania.)
• TrMAD2014  + (4^th Regional Translational Research in Mitochondria, Aging, and Disease Symposium, Pittsburgh, PA, US. [http://www.upci.upmc.edu/trmad/ TrMAD2014])
• 4th Global Chinese Symposium & The 8th Symposium for Cross-straits on Free Radical Biology and Medicine 2018 Macao CN  + (4th Global Chinese Symposium & The 8th Symposium for Cross-straits, Hong Kong and Macao on Free Radical Biology and Medicine, Macao, China, 2018)
• 4th edition Metabolism & Cancer 2021 Virtual  + (4th edition Metabolism & Cancer, Virtu … 4th edition Metabolism & Cancer, Virtual, 2021 </br></br></br>== Program ==</br>:::: [https://www.metabolism-cancer.com/program/ here]</br></br>== Organizers ==</br>:::: The list of organizers can be found [https://www.metabolism-cancer.com/under-construction/ here]</br></br>== Registration ==</br>:::: [https://www.metabolism-cancer.com/registration/ Registration and more information]</br></br>== Oroboros at MetaboCancer 2021==</br>:::: [[Gnaiger Erich]]: Oroboros Instruments innovations - NextGen-O2k and Bioenergetics Communications, ''May 28th at 11:25''</br></br>=== Booth ===</br>:::: The Oroboros team is looking forward to welcome you at our Oroboros booth which will be available at this conference.</br></br></br>== Support ==</br>[[File:Template NextGen-O2k.jpg|right|350px|link=NextGen-O2k]]</br></br>[[Category:NextGen-O2k]]</br>:::: Supported by project NextGen-O2k which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 859770.</br><br/></br><br/></br><br/></br><br/> agreement No. 859770. <br/> <br/> <br/> <br/>)
• MacPherson 2016 Am J Physiol Cell Physiol  + (5'-AMP-activated protein kinase (AMPK) is … 5'-AMP-activated protein kinase (AMPK) is activated as a consequence of lipolysis and has been shown to play a role in regulation of adipose tissue mitochondrial content. Conversely, the inhibition of lipolysis has been reported to potentiate the induction of protein kinase A (PKA)-targeted genes involved in the regulation of oxidative metabolism. The purpose of the current study was to address these apparent discrepancies and to more fully examine the relationship between lipolysis, AMPK, and the β-adrenergic-mediated regulation of gene expression. In 3T3-L1 adipocytes, the adipose tissue triglyceride lipase (ATGL) inhibitor ATGListatin attenuated the Thr(172) phosphorylation of AMPK by a β3-adrenergic agonist (CL 316,243) independent of changes in PKA signaling. Similarly, CL 316,243-induced increases in the Thr(172) phosphorylation of AMPK were reduced in adipose tissue from whole body ATGL-deficient mice. Despite reductions in the activation of AMPK, the induction of PKA-targeted genes was intact or, in some cases, increased. Similarly, markers of mitochondrial content and respiration were increased in adipose tissue from ATGL knockout mice independent of changes in the Thr(172) phosphorylation of AMPK. Taken together, our data provide evidence that AMPK is not required for the regulation of adipose tissue oxidative capacity in conditions of reduced fatty acid release.</br></br>Copyright © 2016 the American Physiological Society.© 2016 the American Physiological Society.)
• Stride 2012 Front Physiol  + (5'-adenosine monophosphate-activated prote … 5'-adenosine monophosphate-activated protein kinase (AMPK) is considered central in regulation of energy status and substrate utilization within cells. In heart failure the energetic state is compromised and substrate metabolism is altered. We hypothesized that this could be linked to changes in AMPK activity and we therefore investigated mitochondrial oxidative phosphorylation capacity from the oxidation of long- and medium-chain fatty acids (LCFA and MCFA) in cardiomyocytes from young and old mice expressing a dominant negative AMPKα2 (AMPKα2-KD) construct and their wildtype (WT) littermates. We found a 35-45% (P < 0.05) lower mitochondrial capacity for oxidizing MCFA in AMPKα2-KD of both age-groups, compared to WT. This coincided with marked decreases in protein expression (19/29%, P < 0.05) and activity (14/21%, P < 0.05) of 3-hydroxyacyl-CoA-dehydrogenase (HAD), in young and old AMPKα2-KD mice, respectively, compared to WT. Maximal LCFA oxidation capacity was similar in AMPKα2-KD and WT mice independently of age implying that LCFA-transport into the mitochondria was unaffected by loss of AMPK activity or progressing age. Expression of regulatory proteins of glycolysis and glycogen breakdown showed equivocal effects of age and genotype. These results illustrate that AMPK is necessary for normal mitochondrial function in the heart and that decreased AMPK activity may lead to an altered energetic state as a consequence of reduced capacity to oxidize MCFA. We did not identify any clear aging effects on mitochondrial function. any clear aging effects on mitochondrial function.)